

Date: 01-02-2024

To,  
Cooperate Relation Department  
The BSE LIMITED  
1<sup>st</sup> Floor, Phiroze leejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

**Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Year Ended on 31<sup>st</sup> December, 2023.**

Please find enclosed herewith Newspaper clippings of Audited Financial Results for the quarter and year ended on **31<sup>st</sup> December, 2023** published in **FREE PRESS JOURNAL** and **NAVSHAKTI** on **1<sup>st</sup> February, 2024** in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on **31<sup>st</sup> January, 2024**.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,  
For Colinz Laboratories Ltd.,

  
Ganesh S. Chitte  
Chief Financial Officer

**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

DT: 01/02/2024

\* NAY-SHAKTI \*

मुंबई, गुरुवार, १ फेब्रुवारी २०२४ | नवशक्ति ११

## COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.  
(CIN NO : L24200MH1986PLC041128)

### EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2023

(Rs. In Lacs)

S. No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		Un-Audited			Un-Audited		Audited
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
1	Revenue from Operations	176.23	186.21	172.26	556.81	556.36	732.70
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	14.63	16.07	13.26	46.07	44.20	15.80
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	14.63	16.07	13.26	46.07	44.20	15.80
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	10.63	12.32	10.26	35.07	32.95	45.74
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	21.93	15.74	8.51	61.19	35.20	45.17
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	251.91	251.91	251.91	251.91
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)						
	1) Basic	0.42	0.49	0.41	1.39	1.31	1.82
	2) Diluted	0.42	0.49	0.41	1.39	1.31	1.82

#### NOTES :-

- The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at [www.bseindia.com](http://www.bseindia.com) and on the Company's website at [www.findoc-cll.in](http://www.findoc-cll.in).
- The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st Jan, 2024.
- Previous figures have been regrouped/ rearranged, wherever necessary.

For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**  
CIN NO : L24200MH1986PLC041128  
Dr. MANI L. S.  
Chairman of the Meeting

MUMBAI.  
31<sup>st</sup> Jan, 2024



\* The Free Press Journal \*

DI - 01/02/24

23

## COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.  
(CIN NO : L24200MH1986PLC041128)

### EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2023

(Rs. In Lacs)

S. No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		Un-Audited			Un-Audited		Audited
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
1	Revenue from Operations	176.23	186.21	172.26	556.81	556.36	732.70
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	14.63	16.07	13.26	46.07	44.20	15.80
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	14.63	16.07	13.26	46.07	44.20	15.80
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	10.63	12.32	10.26	35.07	32.95	45.74
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	21.93	15.74	8.51	61.19	35.20	45.17
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	251.91	251.91	251.91	251.91
7	<b>Earning Per Share (Face value of Rs. 10/- each) (not annualised) (in Rs.)</b>						
	1) Basic	0.42	0.49	0.41	1.39	1.31	1.82
	2) Diluted	0.42	0.49	0.41	1.39	1.31	1.82

**NOTES :-**

- The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at [www.bseindia.com](http://www.bseindia.com) and on the Company's website at [www.findoc-cll.in](http://www.findoc-cll.in).
- The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st Jan, 2024.
- Previous figures have been regrouped/rearranged, wherever necessary.

MUMBAI.  
31<sup>st</sup> Jan, 2024



For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**  
CIN NO : L24200MH1986PLC041128  
**Dr. MANI L. S.**  
Chairman of the Meeting

